Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 905, Issue , 2012, Pages 141-144

  He, Lei ^a   Grecula, John C ^b,c   Ling, Yonghua ^b   Enzerra, Michael D ^a   Ammirati, Mario ^b,c   Kendra, Kari ^b,c   Cavaliere, Robert ^b,c   Mayr, Nina ^b,c   McGregor, John ^b,c   Olencki, Thomas ^b,c   Mrozek, Ewa ^b,c   Matharbootham, Mani ^b,c   Oluigbo, Chima ^b,c   Phelps, Mitch A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bendamustine; LC MS MS, Brain; Liquid chromatography mass spectrometry

Indexed keywords

ACCURACY AND PRECISION; ANIMAL STUDIES; BENDAMUSTINE; BRAIN TISSUE; CALIBRATION CURVES; HUMAN BRAIN; INTERNAL STANDARDS; LC-MS/MS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOWER LIMITS OF QUANTITATIONS; MATRIX EFFECTS; MOUSE BRAIN; POSITIVE MODE; REVERSE PHASE CHROMATOGRAPHY; SELECTED REACTION MONITORING; VALIDATED METHODS;

COLUMN CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; FORMIC ACID; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; METHANOL;

BRAIN;

BENDAMUSTINE; CHLORAMBUCIL; FORMIC ACID; METHANOL; WATER;

ACCURACY; ANIMAL TISSUE; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DETERMINATION; LIQUID CHROMATOGRAPHY; METHANOBACTERIACEAE; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS DEVELOPMENT; PROTEIN PROCESSING; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANIMALS; BRAIN CHEMISTRY; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; LEAST-SQUARES ANALYSIS; MALE; MICE; MICE, INBRED ICR; NITROGEN MUSTARD COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

ANIMALIA;

EID: 84865786583     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.08.013     Document Type: Article

References (25)

1. Patel R.R., Mehta M.P. Clin. Cancer Res. 2007, 13:1675.
2. Soffietti R., Ruda R., Mutani R. J. Neurol. 2002, 249:1357.
3. Persidsky Y., Ramirez S.H., Haorah J., Kanmogne G.D. J. Neuroimmune Pharmacol. 2006, 1:223.
4. Deeken J.F., Loscher W. Clin. Cancer Res. 2007, 13:1663.
5. Scherrmann J.M. Vascul. Pharmacol. 2002, 38:349.
6. Kemper E.M., Boogerd W., Thuis I., Beijnen J.H., van Tellingen O. Cancer Treat. Rev. 2004, 30:415.
7. Liu R., Martuza R.L., Rabkin S.D. Gene Ther. 2005, 12:647.
8. Nicolazzo J.A., Charman S.A., Charman W.N. J. Pharm. Pharmacol. 2006, 58:28.
9. Owen J.S., Melhem M., Passarell J.A., D'Andrea D., Darwish M., Kahl B. Cancer Chemother. Pharmacol. 2010, 66:1039.
10. Kalaycio M. Cancer 2009, 473.
11. Barman Balfour J.A., Goa K.L. Drugs 2001, 2001:631.
12. Cheson B.D., Rummel M.J. J. Clin. Oncol. 2009, 27:1492.
13. Konstantinov S.M., Kostovski A., Topashka-Ancheva M., Genova M., Berger M.R. J. Cancer Res. Clin. Oncol. 2002, 128:271.
14. Treon S.P., Hanzis C., Tripsas C., Ioakimidis L., Patterson C.J., Manning R.J., Sheehy P. Clin. Lymphoma Myeloma Leuk. 2011, 11:133.
15. Leonard J.P., Martin P. Hematology Am. Soc. Hematol. Educ. Program 2010, 2010:259.
16. Wierda W.G., Chiorazzi N., Dearden C., Brown J.R., Montserrat E., Shpall E., Stilgenbauer S., Muneer S., Grever M. Clin. Lymphoma Myeloma Leuk. 2010, 10:369.
17. Glode A.E., Jarkowski A. Pharmacotherapy 2009, 29:1375.
18. Rasschaert M., Schrijvers D., Brande J.V., Bosmans J., Merkle K., Vermorken J.B. Br. J. Cancer 2007, 96:1692.
19. Park H.S., Chiang V.L., Knisely J.P., Raldow A.C., Yu J.B. Expert Rev. Anticancer Ther. 2011, 11:1731.
20. Dubbelman A.C., Tibbed M., Rosing H., Gebretensae A., Nan L., Gorman S.H., Robertson P., Schellens J.H.M., Beijnen J.H. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2012, 893-894:92.
21. Teichert J., Sohr R., Henning L., Baumann F., Schoppmeyer K., Patzak U., Preiss R. Drug Metab. Dispos. 2009, 37:292.
22. Teichert J., Baumann F., Chao Q., Franklin C., Bailey B., Hennig L., Caca K., Schoppmeyer K., Patzak U., Preiss R. Cancer Chemother. Pharmacol. 2007, 59:759.
23. Teichert J., Sohr R., Baumann F., Henning L., Merkle K., Caca K., Preiss R. Drug Metab. Dispos. 2005, 33:984.
24. FDA Guidance for Industry Bioanalytical Method Validation 2001, US Department of Health and Human Service, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
25. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Anal. Chem. 2003, 75:3019.